Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.

Effects of the beta3-adrenoceptor (Adrb3) agonist SR58611A (amibegron) on serotonergic and noradrenergic transmission in the rodent: relevance to its antidepressant/anxiolytic-like profile.

Claustre Y, Leonetti M, Santucci V, Bougault I, Desvignes C, Rouquier L, Aubin N, Keane P, Busch S, Chen Y, Palejwala V, Tocci M, Yamdagni P, Didier M, Avenet P, Le Fur G, Oury-Donat F, Scatton B, Steinberg R.

Neuroscience. 2008 Oct 2;156(2):353-64. doi: 10.1016/j.neuroscience.2008.07.011. Epub 2008 Jul 11.

PMID:
18691638
2.

[Pharmacology of cannabinoid receptors].

Le Fur G, Rinaldi-Carmona M, Barth F, Alexander J.

Bull Acad Natl Med. 2007 Apr-May;191(4-5):933-8; discussion 938-40. French.

PMID:
18225447
3.

[New methods in pharmaceutical research: combinatorial chemistry and high throughput screening].

Schirlin D, Galvan M, Le Fur G.

Bull Acad Natl Med. 2007 Apr-May;191(4-5):727-36; discussion 736-7. French.

PMID:
18225426
4.

CB1 receptor-mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamus.

Béquet F, Uzabiaga F, Desbazeille M, Ludwiczak P, Maftouh M, Picard C, Scatton B, Le Fur G.

Eur J Neurosci. 2007 Dec;26(12):3458-64. Epub 2007 Dec 4.

PMID:
18052990
5.

Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats.

Janiak P, Poirier B, Bidouard JP, Cadrouvele C, Pierre F, Gouraud L, Barbosa I, Dedio J, Maffrand JP, Le Fur G, O'Connor S, Herbert JM.

Kidney Int. 2007 Dec;72(11):1345-57. Epub 2007 Sep 19.

6.

Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users.

Huestis MA, Boyd SJ, Heishman SJ, Preston KL, Bonnet D, Le Fur G, Gorelick DA.

Psychopharmacology (Berl). 2007 Nov;194(4):505-15. Epub 2007 Jul 10.

7.

Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats.

Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C, Chabbert M, Cruccioli N, Pfersdorff C, Roque C, Arnone M, Croci T, Soubrié P, Oury-Donat F, Maffrand JP, Scatton B, Lacheretz F, Le Fur G, Herbert JM, Bensaid M.

Hepatology. 2007 Jul;46(1):122-9.

PMID:
17526015
8.

Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders.

Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Santucci V, Françon D, Alonso R, Stahl SM, Keane P, Avenet P, Scatton B, le Fur G, Griebel G.

Neuropsychopharmacology. 2008 Feb;33(3):574-87. Epub 2007 Apr 25.

9.

[Round table chaired by Laurent Broomhead].

Ménard J, Le Fur G, Le Pecq JB, Saliou P, Weissenbach J, Potier P.

Ann Pharm Fr. 2005 Sep;63(5):312-28. French. No abstract available.

PMID:
16385780
10.

The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes.

Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, Bensaid M.

Mol Pharmacol. 2006 Feb;69(2):471-8. Epub 2005 Nov 9.

PMID:
16282221
11.

The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.

Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Péleraux A, Pénarier G, Soubrié P, Le Fur G, Galiègue S, Casellas P.

FASEB J. 2005 Sep;19(11):1567-9. Epub 2005 Jul 11.

PMID:
16009704
12.

Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation.

Bouaboula M, Hilairet S, Marchand J, Fajas L, Le Fur G, Casellas P.

Eur J Pharmacol. 2005 Jul 11;517(3):174-81.

PMID:
15987634
13.

The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor.

Steinwall M, Bossmar T, Brouard R, Laudanski T, Olofsson P, Urban R, Wolff K, Le-Fur G, Akerlund M.

Gynecol Endocrinol. 2005 Feb;20(2):104-9.

PMID:
15823830
14.

Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease.

Mesnage V, Houeto JL, Bonnet AM, Clavier I, Arnulf I, Cattelin F, Le Fur G, Damier P, Welter ML, Agid Y.

Clin Neuropharmacol. 2004 May-Jun;27(3):108-10.

PMID:
15190231
15.

SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.

Rinaldi-Carmona M, Barth F, Congy C, Martinez S, Oustric D, Pério A, Poncelet M, Maruani J, Arnone M, Finance O, Soubrié P, Le Fur G.

J Pharmacol Exp Ther. 2004 Sep;310(3):905-14. Epub 2004 May 6.

PMID:
15131245
16.

SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl]amino]propanoyl)amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl]phenyl)-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization.

Gougat J, Ferrari B, Sarran L, Planchenault C, Poncelet M, Maruani J, Alonso R, Cudennec A, Croci T, Guagnini F, Urban-Szabo K, Martinolle JP, Soubrié P, Finance O, Le Fur G.

J Pharmacol Exp Ther. 2004 May;309(2):661-9. Epub 2004 Jan 27.

PMID:
14747609
17.

SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor.

Serradeil-Le Gal C, Valette G, Foulon L, Germain G, Advenier C, Naline E, Bardou M, Martinolle JP, Pouzet B, Raufaste D, Garcia C, Double-Cazanave E, Pauly M, Pascal M, Barbier A, Scatton B, Maffrand JP, Le Fur G.

J Pharmacol Exp Ther. 2004 Apr;309(1):414-24. Epub 2004 Jan 13.

PMID:
14722330
18.

Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression.

Alonso R, Griebel G, Pavone G, Stemmelin J, Le Fur G, Soubrié P.

Mol Psychiatry. 2004 Mar;9(3):278-86, 224.

PMID:
14699428
19.

Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716.

Hilairet S, Bouaboula M, Carrière D, Le Fur G, Casellas P.

J Biol Chem. 2003 Jun 27;278(26):23731-7. Epub 2003 Apr 10.

20.

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.

Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrié P.

Mol Pharmacol. 2003 Apr;63(4):908-14.

PMID:
12644592
21.
22.

SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.

Emonds-Alt X, Proietto V, Steinberg R, Oury-Donat F, Vigé X, Vilain P, Naline E, Daoui S, Advenier C, Le Fur G, Maffrand JP, Soubrié P, Pascal M.

J Pharmacol Exp Ther. 2002 Dec;303(3):1171-9.

PMID:
12438541
23.

Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.

Serradeil-Le Gal C, Wagnon J, Valette G, Garcia G, Pascal M, Maffrand JP, Le Fur G.

Prog Brain Res. 2002;139:197-210. Review.

PMID:
12436936
24.

Expression profile and up-regulation of PRAX-1 mRNA by antidepressant treatment in the rat brain.

Chardenot P, Roubert C, Galiègue S, Casellas P, Le Fur G, Soubrié P, Oury-Donat F.

Mol Pharmacol. 2002 Dec;62(6):1314-20.

PMID:
12435798
25.

Targeted inactivation of the neurotensin type 1 receptor reveals its role in body temperature control and feeding behavior but not in analgesia.

Remaury A, Vita N, Gendreau S, Jung M, Arnone M, Poncelet M, Culouscou JM, Le Fur G, Soubrié P, Caput D, Shire D, Kopf M, Ferrara P.

Brain Res. 2002 Oct 25;953(1-2):63-72.

PMID:
12384239
26.

Research strategies in the pharmaceutical industry to cope with the problems of ageing.

Le Fur G, Guillot F, Alexander J, Muller JC.

C R Biol. 2002 Jun;325(6):643-54.

PMID:
12360852
27.

Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors.

Landi M, Croci T, Rinaldi-Carmona M, Maffrand JP, Le Fur G, Manara L.

Eur J Pharmacol. 2002 Aug 16;450(1):77-83.

PMID:
12176112
28.

Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist.

Emonds-Alt X, Proietto V, Steinberg R, Advenier C, Daoui S, Naline E, Gueudet C, Michaud JC, Oury-Donat F, Poncelet M, Vilain P, Le Fur G, Maffrand JP, Soubrié P, Pascal M.

Can J Physiol Pharmacol. 2002 May;80(5):482-8.

PMID:
12056557
29.

Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon.

Manara L, Croci T, Guagnini F, Rinaldi-Carmona M, Maffrand JP, Le Fur G, Mukenge S, Ferla G.

Dig Liver Dis. 2002 Apr;34(4):262-9.

PMID:
12038810
30.

[Design and birth of drugs].

Maffrand JP, Lehner JP, Le Fur G.

Rev Prat. 2002 Mar 1;52(5):482-5. French.

PMID:
11949498
31.

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization.

Gully D, Geslin M, Serva L, Fontaine E, Roger P, Lair C, Darre V, Marcy C, Rouby PE, Simiand J, Guitard J, Gout G, Steinberg R, Rodier D, Griebel G, Soubrie P, Pascal M, Pruss R, Scatton B, Maffrand JP, Le Fur G.

J Pharmacol Exp Ther. 2002 Apr;301(1):322-32.

PMID:
11907190
32.

Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.

Serradeil-Le Gal C, Wagnon J, Simiand J, Griebel G, Lacour C, Guillon G, Barberis C, Brossard G, Soubrié P, Nisato D, Pascal M, Pruss R, Scatton B, Maffrand JP, Le Fur G.

J Pharmacol Exp Ther. 2002 Mar;300(3):1122-30.

PMID:
11861823
33.

Permissive role of neurokinin NK(3) receptors in NK(1) receptor-mediated activation of the locus coeruleus revealed by SR 142801.

Bert L, Rodier D, Bougault I, Allouard N, Le-Fur G, Soubrié P, Steinberg R.

Synapse. 2002 Jan;43(1):62-9.

PMID:
11746734
34.

Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function.

Steinberg R, Alonso R, Griebel G, Bert L, Jung M, Oury-Donat F, Poncelet M, Gueudet C, Desvignes C, Le Fur G, Soubrié P.

J Pharmacol Exp Ther. 2001 Nov;299(2):449-58.

PMID:
11602654
35.

Effects of the selective activation of 5-HT3 receptors on sleep: a polysomnographic study in healthy volunteers.

Staner L, Linker T, Toussaint M, Danjou P, Roegel JC, Luthringer R, Le Fur G, Macher JP.

Eur Neuropsychopharmacol. 2001 Aug;11(4):301-5.

PMID:
11532385
36.

Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction.

Mas-Nieto M, Pommier B, Tzavara ET, Caneparo A, Da Nascimento S, Le Fur G, Roques BP, Noble F.

Br J Pharmacol. 2001 Apr;132(8):1809-16.

37.

Selective blockade of vasopressin V2 receptors reveals significant V2-mediated water reabsorption in Brattleboro rats with diabetes insipidus.

Pouzet B, Serradeil-Le Gal C, Bouby N, Maffrand JP, Le Fur G, Bankir L.

Nephrol Dial Transplant. 2001 Apr;16(4):725-34.

PMID:
11274265
38.

Erratum to: "The agonist SR 146131 and the antagonist SR 27897 occupy different sites on the human CCK(1) receptor"

Gouldson P, Legoux P, Carillon C, Delpech B, Le Fur G, Ferrara P, Shire D.

Eur J Pharmacol. 2000 Nov 3;407(3):333. No abstract available.

PMID:
11068031
39.

The agonist SR 146131 and the antagonist SR 27897 occupy different sites on the human CCK(1) receptor.

Gouldson P, Legoux P, Carillon C, Delpech B, Le Fur G, Ferrara P, Shire D.

Eur J Pharmacol. 2000 Jul 21;400(2-3):185-94. Erratum in: Eur J Pharmacol 2000 Nov 3;407(3):333.

PMID:
10988332
40.

Functional assessment of beta adrenoceptor subtypes in human colonic circular and longitudinal (taenia coli) smooth muscle.

Manara L, Croci T, Aureggi G, Guagnini F, Maffrand JP, Le Fur G, Mukenge S, Ferla G.

Gut. 2000 Sep;47(3):337-42.

41.

Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor.

Gouldson P, Calandra B, Legoux P, Kernéis A, Rinaldi-Carmona M, Barth F, Le Fur G, Ferrara P, Shire D.

Eur J Pharmacol. 2000 Jul 28;401(1):17-25.

PMID:
10915832
42.

Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension.

Lacheretz F, Barbier A, Serradeil-Le Gal C, Elena PP, Maffrand JP, Le Fur G.

J Ocul Pharmacol Ther. 2000 Jun;16(3):203-16.

PMID:
10872918
43.

Characterization of NPY receptors controlling lipolysis and leptin secretion in human adipocytes.

Serradeil-Le Gal C, Lafontan M, Raufaste D, Marchand J, Pouzet B, Casellas P, Pascal M, Maffrand JP, Le Fur G.

FEBS Lett. 2000 Jun 16;475(2):150-6.

44.

Essential role of extracellular charged residues of the human CCK(1) receptor for interactions with SR 146131, SR 27897 and CCK-8S.

Gouldson P, Legoux P, Carillon C, Dumont X, Le Fur G, Ferrara P, Shire D.

Eur J Pharmacol. 2000 Feb 18;389(2-3):115-24.

PMID:
10688974
45.

Contrasting roles of leu(356) in the human CCK(1) receptor for antagonist SR 27897 and agonist SR 146131 binding.

Gouldson P, Legoux P, Carillon C, Delpech B, Le Fur G, Ferrara P, Shire D.

Eur J Pharmacol. 1999 Nov 3;383(3):339-46.

PMID:
10594328
46.

Peripheral benzodiazepine receptor agonists exhibit potent antiapoptotic activities.

Bono F, Lamarche I, Prabonnaud V, Le Fur G, Herbert JM.

Biochem Biophys Res Commun. 1999 Nov 19;265(2):457-61.

PMID:
10558889
47.

Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor.

Calandra B, Portier M, Kernéis A, Delpech M, Carillon C, Le Fur G, Ferrara P, Shire D.

Eur J Pharmacol. 1999 Jun 25;374(3):445-55.

PMID:
10422789
48.

Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils.

Poncelet M, Barnouin MC, Brelière JC, Le Fur G, Soubrié P.

Psychopharmacology (Berl). 1999 May;144(2):144-50.

PMID:
10394995
49.
50.

Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex.

Labie C, Lafon C, Marmouget C, Saubusse P, Fournier J, Keane PE, Le Fur G, Soubrié P.

Br J Pharmacol. 1999 May;127(1):139-44.

Supplemental Content

Loading ...
Support Center